Cargando…

Safety of anti‐SARS‐CoV‐2 messenger RNA vaccine in lung cancer patients undergoing anticancer chemotherapy: A multicenter, prospective, observational, patient‐reported outcome study

BACKGROUND: COVID‐19 incidence is high in patients with cancer. The fatality rate was high for the Delta variant, necessitating infection prevention by vaccination. This study evaluated the safety of a SARS‐CoV‐2 vaccine in patients with advanced lung cancer receiving anticancer therapy. METHODS: We...

Descripción completa

Detalles Bibliográficos
Autores principales:	Harada, Daijiro, Tamura, Tomoki, Ninomiya, Kiichiro, Kubo, Toshio, Kuyama, Shoichi, Tachibana, Sayaka, Inoue, Koji, Chikamori, Kenichi, Kudo, Kenichiro, Ochi, Nobuaki, Maeda, Yoshinobu, Kiura, Katsuyuki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons Australia, Ltd 2022
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9870727/ https://www.ncbi.nlm.nih.gov/pubmed/36404396 http://dx.doi.org/10.1111/1759-7714.14737

Ejemplares similares

Short‐term safety of an anti‐severe acute respiratory syndrome coronavirus 2 messenger RNA vaccine for patients with advanced lung cancer treated with anticancer drugs: A multicenter, prospective, observational study
por: Tamura, Tomoki, et al.
Publicado: (2021)

A phase I/II trial of weekly nab‐paclitaxel for pretreated non‐small‐cell lung cancer patients without epidermal growth factor receptor mutations and anaplastic lymphoma kinase rearrangement
por: Harada, Daijiro, et al.
Publicado: (2019)

Utility of immune checkpoint inhibitors in non‐small‐cell lung cancer patients with poor performance status
por: Kano, Hirohisa, et al.
Publicado: (2020)

Clinical significance of repeat rebiopsy in detecting the EGFR T790M secondary mutation in patients with non-small cell lung cancer
por: Ichihara, Eiki, et al.
Publicado: (2018)

MET or NRAS amplification is an acquired resistance mechanism to the third-generation EGFR inhibitor naquotinib
por: Ninomiya, Kiichiro, et al.
Publicado: (2018)

Combined effect of cabozantinib and gefitinib in crizotinib‐resistant lung tumors harboring ROS1 fusions
por: Kato, Yuka, et al.
Publicado: (2018)

Downregulation of TBXAS1 in an iron-induced malignant mesothelioma model
por: Minami, Daisuke, et al.
Publicado: (2015)

Marginal Zone Lymphoma and Lung Adenocarcinoma with an EGFR Exon 19 E746-S752del Mutation in a Patient with IgG4-related Disease
por: Okawa, Sachi, et al.
Publicado: (2021)

Pulmonary Aspergilloma and Allergic Bronchopulmonary Aspergillosis Following the 2018 Heavy Rain Event in Western Japan
por: Ando, Eri, et al.
Publicado: (2021)

Transcatheter embolization for idiopathic peripheral pulmonary arterial aneurysm: A case report
por: Tamura, Tomoki, et al.
Publicado: (2019)

Successful and Prompt Treatment with Tepotinib for Lung Adenocarcinoma Harboring MET Exon 14 Skipping Mutation Combined with Lung Abscess Formation: A Case Report
por: Makimoto, Go, et al.
Publicado: (2022)

Successful Desensitization Treatment with Osimertinib after the Development of Osimertinib-induced Urticaria in a Patient Undergoing Treatment for Non-small Cell Lung Cancer Harboring the EGFR T790M Mutation
por: Makimoto, Go, et al.
Publicado: (2020)

Massive hemoptysis in a post-operative patient with recurrent lung cancer successfully treated by the combination therapy of Endobronchial Watanabe Spigot and bronchial artery embolization
por: Taoka, Masataka, et al.
Publicado: (2022)

Triple therapy with osimertinib, bevacizumab and cetuximab in EGFR-mutant lung cancer with HIF-1α/TGF-α expression
por: Nishii, Kazuya, et al.
Publicado: (2021)

Demand for weekend outpatient chemotherapy among patients with cancer in Japan
por: Katayama, Hideki, et al.
Publicado: (2020)

Managing Lung Cancer with Comorbid Interstitial Pneumonia
por: Ichihara, Eiki, et al.
Publicado: (2019)

The Role of STAT3 in Non-Small Cell Lung Cancer
por: Harada, Daijiro, et al.
Publicado: (2014)

Dramatic Response of Brain Metastasis from EGFR-mutation-positive NSCLC to Dacomitinib
por: Kudo, Kenichiro, et al.
Publicado: (2020)

Fulminant Myocarditis for Non-small-cell Carcinoma of the Lung with Nivolumab and Ipilimumab Plus Chemotherapy
por: Nishimura, Tomoka, et al.
Publicado: (2022)

Identification of targetable kinases in idiopathic pulmonary fibrosis
por: Higo, Hisao, et al.
Publicado: (2022)

Nintedanib can be used safely and effectively for idiopathic pulmonary fibrosis with predicted forced vital capacity ≤ 50%: A multi-center retrospective analysis
por: Senoo, Satoru, et al.
Publicado: (2020)

Pneumocystis Pneumonia Concomitant with Ectopic ACTH Syndrome Caused by a Large Cell Neuroendocrine Carcinoma of the Thymus
por: Oda, Naohiro, et al.
Publicado: (2017)

Rapid and Long-term Response of Pulmonary Pleomorphic Carcinoma to Nivolumab
por: Senoo, Satoru, et al.
Publicado: (2018)

Efficacy of multimodal treatment for leptomeningeal metastases in a lung cancer harboring an EGFR mutation
por: Morichika, Daisuke, et al.
Publicado: (2016)

Cisplatin-induced hyponatremia in malignancy: comparison between brand-name and generic formulation
por: Ochi, Nobuaki, et al.
Publicado: (2014)

Obstructive jaundice at the initial presentation in small-cell lung cancer
por: Ochi, Nobuaki, et al.
Publicado: (2010)

Congestive Heart Failure During Osimertinib Treatment for Epidermal Growth Factor Receptor (EGFR)-mutant Non-small Cell Lung Cancer (NSCLC)
por: Watanabe, Hiromi, et al.
Publicado: (2017)

Interstitial Pneumonia Secondary to Hermansky-Pudlak Syndrome Type 4 Treated with Different Antifibrotic Agents
por: Itano, Junko, et al.
Publicado: (2020)

The Effect of Pleural Effusion on Prognosis in Patients with Non-Small Cell Lung Cancer Undergoing Immunochemotherapy: A Retrospective Observational Study
por: Nishimura, Tomoka, et al.
Publicado: (2022)

CDK4/6 signaling attenuates the effect of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer
por: Hara, Naofumi, et al.
Publicado: (2023)

VEGFR2 blockade augments the effects of tyrosine kinase inhibitors by inhibiting angiogenesis and oncogenic signaling in oncogene‐driven non‐small‐cell lung cancers
por: Watanabe, Hiromi, et al.
Publicado: (2021)

Efficacy of gilteritinib in comparison with alectinib for the treatment of ALK‐rearranged non‐small cell lung cancer
por: Ando, Chihiro, et al.
Publicado: (2023)

Successful Re-administration of Osimertinib in Osimertinib-induced Interstitial Lung Disease with an Organizing Pneumonia Pattern: A Case Report and Literature Review
por: Itano, Junko, et al.
Publicado: (2019)

Successful Treatment with Lorlatinib after the Development of Alectinib-Induced Liver Damage in ALK-Positive Non-Small-Cell Lung Cancer: A Case Report
por: Makimoto, Go, et al.
Publicado: (2021)

Retrobulbar Optic Neuritis Induced by Pembrolizumab in a Patient with Lung Adenocarcinoma
por: Kawakado, Keita, et al.
Publicado: (2021)

Limited effect of afatinib in a non‐small cell lung cancer patient harboring an epidermal growth factor receptor K860I missense mutation: A case report
por: Tamura, Tomoki, et al.
Publicado: (2021)

Triplet therapy with afatinib, cetuximab, and bevacizumab induces deep remission in lung cancer cells harboring EGFR T790M in vivo
por: Kudo, Kenichiro, et al.
Publicado: (2017)

Dasatinib-induced massive left chylothorax in a patient with chronic myeloid leukemia
por: Makimoto, Go, et al.
Publicado: (2022)

Dramatic Response to Carboplatin Plus Paclitaxel in Pancreatic Mucinous Cystadenocarcinoma with Liver Metastasis
por: Oda, Naohiro, et al.
Publicado: (2021)

Estimated Glomerular Filtration Rate —A More Stable Indicator than Creatinine Clearance in Peritoneal Dialysis Practice
por: Maeda, Yoshitaka, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_358ibqt2apmevqff64qp2c5a0u